<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04134390</url>
  </required_header>
  <id_info>
    <org_study_id>CABOMAYOR</org_study_id>
    <secondary_id>2019-001639-30</secondary_id>
    <nct_id>NCT04134390</nct_id>
  </id_info>
  <brief_title>Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR Study</brief_title>
  <acronym>CABOMAYOR</acronym>
  <official_title>Pilot Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Oncology Genito-Urinary Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Apices Soluciones S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Oncology Genito-Urinary Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aged fragile patients are not usually included in clinical trials and efficacy and&#xD;
      tolerability of the different available treatments in this population are unknown.&#xD;
&#xD;
      Conversely, ageing has been associated with a decrease in the efficacy of immune checkpoint&#xD;
      inhibitors due to a decline in the effectiveness of the immune system (immunosenescence). In&#xD;
      the Checkmate 025 trial comparing nivolumab with everolimus, the Hazard Ratio (HR) in&#xD;
      patients older than 75 years old favoured everolimus, 1.23 (0.66-2.31). Thus, TKis might be a&#xD;
      better treatment option for this population. However, the absence of data and concerns about&#xD;
      possible secondary effects associated, can preclude clinicians to treat aged fragile patients&#xD;
      with cabozantinib. A pilot phase II trial would help to have data on safety and efficacy of&#xD;
      cabozantinib in this aged fragile population.&#xD;
&#xD;
      In METEOR trial around 60% of patients reduced the dose of cabozantinib because of toxicity&#xD;
      and tolerance problems. It is suspected that the efficacy of cabozantinib in the population&#xD;
      to be included in this trial (aged and fragile) will be similar to that observed in CABOSUN&#xD;
      trial (disease control rate around 75%). However, there is no information available in this&#xD;
      group of patients. On the other hand, in the &gt;75 years old subgroup within the METEOR trial,&#xD;
      37% discontinued due to adverse events, 85% needed dose reductions and median average daily&#xD;
      dose was 33,6 mg. For this reason, the cabozantinib initial dose chosen for patients to be&#xD;
      included in this study is 40 mg/day.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 17, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Cabozantinib 40 mg per os (p.o.) once daily in 28-day cycles. Dose can be escalated to 60 mg to avoid suboptimal exposure to the drug if 40 mg is considered tolerated. If the dose of 40 mg is not tolerated, a de-escalation to 20 mg, temporary interruption, or stopping cabozantinib will be possible.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Complete Response (CR) evaluated by Evaluation Criteria In Solid Tumors (RECIST) 1.1 according to investigator criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Partial Response (PR) evaluated by Evaluation Criteria In Solid Tumors (RECIST) 1.1 according to investigator criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Adverse Events (AEs) experienced by patients. AEs will be assessed according to National Cancer Institute-Common Terminology Criteria (NCI-CTC) v 5.0 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Complete Response (CR) evaluated by RECIST 1.1 criteria according to investigator criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Partial Response (PR) evaluated by RECIST 1.1 criteria according to investigator criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Stable Disease (SD) evaluated by RECIST 1.1 criteria according to investigator criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Since the patient's study enrolment until patient progression, assessed up to 24 months</time_frame>
    <description>Time in months since the patient's study enrolment until patient progression according to RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Since the patient's study enrolment until death assessed up to 24 months</time_frame>
    <description>It is time in months since the patient's study enrolment until death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Old Age; Debility</condition>
  <condition>Renal Carcinoma Metastatic</condition>
  <arm_group>
    <arm_group_label>Cabozantinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cabozantinib 40 mg p.o. once daily in 28-day cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabozantinib</intervention_name>
    <description>Subjects will receive cabozantinib 40mg p.o. as long as they continue to experience clinical benefit or until unacceptable toxicity, the need for alternative anticancer treatment, or other reasons for treatment discontinuation</description>
    <arm_group_label>Cabozantinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Documented histological or cytological diagnosis of renal cell cancer.&#xD;
&#xD;
          2. Measurable disease per RECIST 1.1 as determined by the investigator.&#xD;
&#xD;
          3. Metastatic disease.&#xD;
&#xD;
          4. Patient must have signed the informed consent document.&#xD;
&#xD;
          5. Capable of understanding and complying with the protocol requirements.&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group Performance Status (ECOG-PS) 0-2.&#xD;
&#xD;
          7. Patients aged &gt;70 years old with Society of Geriatric Oncology (SIOG) defined fragile&#xD;
             population or patients &gt;75 years with or without SIOG defined fragility.&#xD;
&#xD;
          8. No previous treatment for Metastatic Renal Cell Carcinoma (mRCC)&#xD;
&#xD;
          9. Adequate organ function based on standard laboratory tests including haematology,&#xD;
             serum chemistry, lipids, coagulation, thyroid function, and urinalysis.&#xD;
&#xD;
         10. Sexually active fertile subjects and their partners must agree to use medically&#xD;
             accepted methods of contraception (eg, barrier methods, including male condom, female&#xD;
             condom, or diaphragm with spermicidal gel) during the course of the study and for 4&#xD;
             months after the last dose of study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous treatment for mRCC.&#xD;
&#xD;
          2. Radiation therapy for bone metastasis within 2 weeks, any other external radiation&#xD;
             therapy within 4 weeks before inclusion.&#xD;
&#xD;
          3. Known brain metastases or cranial epidural disease unless adequately treated and&#xD;
             stable for at least 3 months before inclusion.&#xD;
&#xD;
          4. Concomitant anticoagulation at therapeutic doses with oral anticoagulants or platelet&#xD;
             inhibitors.&#xD;
&#xD;
          5. Chronic treatment with corticosteroids or other immunosuppressive agents&#xD;
&#xD;
          6. Uncontrolled, significant intercurrent or recent illness including, but not limited&#xD;
             to, the following conditions: Cardiovascular disorders, Gastrointestinal (GI)&#xD;
             disorders including those associated with a high risk of perforation or fistula&#xD;
             formation, Clinically significant hematuria, hematemesis, or hemoptysis of &gt; 0.5&#xD;
             teaspoon of red blood, or other history of significant bleeding (eg, pulmonary&#xD;
             hemorrhage) within 3 months before inclusion, Cavitating pulmonary lesion(s) or known&#xD;
             endobronchial disease manifestation and/or Lesions invading major pulmonary blood&#xD;
             vessels.&#xD;
&#xD;
          7. Major surgery within 2 months before inclusion.&#xD;
&#xD;
          8. Corrected QT interval calculated by the Fridericia formula (QTcF) &gt; 500 msec within 10&#xD;
             days before inclusion.&#xD;
&#xD;
          9. Inability to swallow tablets or capsules.&#xD;
&#xD;
         10. Previously identified allergy or hypersensitivity to components of the study treatment&#xD;
             formulation.&#xD;
&#xD;
         11. Diagnosis of another malignancy within 2 years before inclusion, except for&#xD;
             superficial skin cancers, or localized, low grade tumors deemed cured and not treated&#xD;
             with systemic therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel A Climent, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FIVO</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabel Grau</last_name>
    <phone>+34610286915</phone>
    <email>trialmanager@sogug.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Carlos Villa</last_name>
    </contact>
    <investigator>
      <last_name>Juan Carlos Villa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO L'Hospitalet</name>
      <address>
        <city>L'Hospitalet De Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucía Heras</last_name>
    </contact>
    <investigator>
      <last_name>Lucía Heras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Insular de Gran Canarias</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisenda Francina Llabrés Valentí</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Lucus Augusti</name>
      <address>
        <city>Lugo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalia Fernandez</last_name>
    </contact>
    <investigator>
      <last_name>Natalia Fernandez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Sofia</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Zambrana, MD</last_name>
    </contact>
    <investigator>
      <last_name>Francisco Zambrana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Donostia</name>
      <address>
        <city>San Sebastián</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Basterretxea, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laura Basterretxea, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundación Instituto Valenciano de Oncologia</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel A Climent, MD</last_name>
      <phone>+34 961114050</phone>
      <email>macliment@fivo.org</email>
    </contact>
    <investigator>
      <last_name>Miguel A Climent, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Doctor Peset</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dolores Torregrosa</last_name>
    </contact>
    <investigator>
      <last_name>Dolores Torregrosa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regina Gironés, MD</last_name>
    </contact>
    <investigator>
      <last_name>Regina Gironés, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Sanchez</last_name>
    </contact>
    <investigator>
      <last_name>Ricardo Sanchez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 15, 2019</study_first_submitted>
  <study_first_submitted_qc>October 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2019</study_first_posted>
  <last_update_submitted>November 12, 2020</last_update_submitted>
  <last_update_submitted_qc>November 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fragile</keyword>
  <keyword>renal carcinoma</keyword>
  <keyword>old age</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Frailty</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

